z-logo
open-access-imgOpen Access
Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.
Author(s) -
Hideki Ijichi,
Tomoharu Yoshizumi,
Toru Ikegami,
Yuji Soejima,
Tetsuo Ikeda,
Hirofumi Kawanaka,
Hideaki Uchiyama,
Yo-Ichi Yamashita,
Masaru Morita,
Eiji Oki,
Koshi Mimori,
Keishi Sugimachi,
Hiroshi Saeki,
Masayuki Watanabe,
Ken Shirabe,
Yoshihiko Maehara
Publication year - 2013
Publication title -
fukuoka igaku zasshi = hukuoka acta medica
Language(s) - English
DOI - 10.15017/1398607
Hepatitis B virus (HBV) recurrence after liver transplantation for HBV-associated liver diseases results in decreased patient and graft survival. Herein we have reported two cases of HBV recurrence following relapse of hepatocellular carcinoma (HCC) after living donor liver transplantation (LDLT). Both cases had LDLT for end-stage liver disease secondary to HBV infection with nodules of HCC exceeding the Milan criteria. HBV prophylaxis using hepatitis B immunoglobulin with nucleos (t) ide analogues were given and HBV DNA levels were consistently undetectable after LDLT. HCC recurred at 5 months and 13 months posttransplant respectively, and chemotherapy and radiation therapy were performed. HBV recurrence occurred during the treatment of HCC. HBV DNA levels increased despite the treatment with anti-HBV agents after HBV recurrence. In hepatitis B surface antigen positive recipients, HBV prophylaxis should be intensified during the treatment of recurrent HCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom